TNA
ABBV icon

True North Advisors’s AbbVie ABBV Stock Holding History

True North Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96M Sell
15,735
-2,892
-16% -$622K 0.38% 50
2026
Q1 		$4.05M Buy
18,627
+16
+0.1% +$3.55K 0.46% 42
2025
Q4 		$4.25M Buy
18,611
+406
+2% +$92.5K 0.55% 34
2025
Q3 		$4.22M Buy
18,205
+1,011
+6% +$206K 0.67% 24
2025
Q2 		$3.19M Sell
17,194
-6,499
-27% -$1.21M 0.61% 33
2025
Q1 		$4.96M Sell
23,693
-2,362
-9% -$459K 0.88% 20
2024
Q4 		$4.63M Buy
26,055
+20,553
+374% +$3.78M 1.09% 13
2024
Q3 		$1.09M Sell
5,502
-20
-0.4% -$3.73K 0.28% 61
2024
Q2 		$947K Sell
5,522
-1,107
-17% -$183K 0.25% 65
2024
Q1 		$1.21M Buy
6,629
+118
+2% +$20.3K 0.33% 54
2023
Q4 		$1.01M Sell
6,511
-169
-3% -$24.6K 0.26% 57
2023
Q3 		$996K Sell
6,680
-161
-2% -$23.6K 0.31% 60
2023
Q2 		$922K Buy
6,841
+2,109
+45% +$309K 0.26% 76
2023
Q1 		$754K Buy
4,732
+426
+10% +$65.1K 0.22% 103
2022
Q4 		$696K Buy
4,306
+676
+19% +$104K 0.24% 92
2022
Q3 		$487K Sell
3,630
-342
-9% -$49.1K 0.16% 117
2022
Q2 		$608K Buy
+3,972
New +$607K 0.19% 106
2022
Q1 		– Sell
-6,445
Closed -$872K – 198
2021
Q4 		$872K Sell
6,445
-3,977
-38% -$470K 0.15% 117
2021
Q3 		$1.12M Buy
10,422
+2,786
+36% +$318K 0.22% 98
2021
Q2 		$860K Buy
7,636
+431
+6% +$48.5K 0.18% 104
2021
Q1 		$779K Sell
7,205
-1,248
-15% -$133K 0.18% 100
2020
Q4 		$905K Buy
8,453
+991
+13% +$95.2K 0.23% 83
2020
Q3 		$653K Buy
7,462
+158
+2% +$14.9K 0.19% 93
2020
Q2 		$717K Buy
7,304
+4,205
+136% +$370K 0.17% 97
2020
Q1 		$236K Buy
3,099
+18
+0.6% +$1.53K 0.08% 108
2019
Q4 		$272K Buy
+3,081
New +$256K 0.08% 88

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

True North Advisors's ABBV Position: Q2 2026 in Review

True North Advisors reduced its AbbVie (ABBV) stake by 16% in Q2 2026, selling an estimated $622K and leaving 15,735 shares worth $3.96M. The position accounts for 0.38% of the portfolio, ranked #50.

True North Advisors first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $4.96M in Q1 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • True North Advisors held 15,735 shares of AbbVie worth $3.96M as of Q2 2026.
  • True North Advisors sold 2,892 AbbVie shares in Q2 2026, an estimated $622K.
  • AbbVie made up 0.38% of True North Advisors's portfolio in Q2 2026, its #50 holding.
  • True North Advisors first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • True North Advisors's AbbVie position peaked at $4.96M in Q1 2025.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on True North Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.